Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 54, Issue 6, 1996, Pages 385-402

  Jeremy, J Y ^a   Jackson, C L ^a   Bryan, A J ^a   Angelini, G D ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; ICOSANOID; NONSTEROID ANTIINFLAMMATORY AGENT; POLYUNSATURATED FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN;

CELL ADHESION; CORONARY ARTERY BYPASS GRAFT; DIET; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0029829091     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90022-8     Document Type: Review

References (298)

1. Woolf N. Pathology of atherosclerosis. Br Med Bull 1990; 46:960-985.
2. Meade T. W. Epidemiology of atheroma, thrombosis and ischaemic heart disease. In: Bloom A. L., Thomas D. P. (eds). Haemostasis and Thrombosis. Churchill Livingstone, London. 1987; 697-720.
3. Demke D. M. Prostaglandins in percutaneous transluminal coronary angioplasty. In: Vane J., O'Grady J. (eds). Therapeutic applications of prostaglandins. Edward Arnold, London 1993; 175-186.
4. Holmes D. R. Jr, Vliestra R. E. Percutaneous transluminal coronary angioplasty: current status and future trends. Mayo Clin Proc. 1986; 61: 865-876.
5. Bach R., Jung F., Kohsiek I. et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. Thombos Res 1994; 74: S55-267.
6. McBride W., Lange R. A., Hillis L. D. Restenosis after successful coronary angioplasty. N Engl J Med 1988; 318: 1734-1737.
7. Guiteras Val P., Bourassa M. G., David P. R. et al. Restenosis after successful percutaneous transluminal coronary angioplasty. Am J Cardiol. 1987; 60: 50B-55B.
8. Angelini G. D., Newby A. C. The future of saphenous vein as a coronary artery conduit. Eur Heart Surg 1989; 10: 273-280.
9. Izzat M. B., Angelini G. D. Arterial conduits In myocardial neovascularization. Surgery 1994; 37-41.
10. Angelini G. D. Saphenous vein graft failure: etiologic considerations and strategies for prevention. Curr Opin Cardiol Cardiol 1992; 7: 939-944.
11. Jeremy J. Y., Bryan A. J., Angelini G. D. The pathophysiology and treatment of myointimal hyperplasia. J Drug Develop Clin Prac. 1995; In press.
12. Steele P. M., Cheseboro J. H., Stanson A. W. et al. Balloon angioplasty: a natural history of the pathophysiological response to injury in a pig model. Circ Res. 1985; 57: 105-112.
13. Bryan A. J., Angelini G. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 1994; 9: 641-649.
14. Davies M. G., Hagen P.-O. Pathobiology of intimai hyperplasia. Br J 1994; 81: 1254-1269.
15. Nikol S., Huebens T. Y., Gonschlor P., Hofling B. Myointimal hyperplasia. Crit Ischaemia 1995 5: 15-27
16. Clowes A. W., Reidy M. A., Clowes M. M. Kinetics of cellular proliferation after arterial injury. Lab Invest 1983; 49: 208-215.
17. Chervu A., Moore W. S. An overview of intimal hyperplasia. Surg Gynecol Obstet 1990; 171: 433-447
18. Endean E. D. Cellular mechanisms in the development of intimal hyperplasia: an overview. In: Dobrin P. B. (ed) Intimal hyperplasia. RG Landes Co, Austin 1994; 141-175.
19. Ip J. H., Fuster V., Badimon L. et al. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687.
20. Clowes A. W., Reidy M. A. Prevention of stenosis after vascular reconstruction. Pharmacologic control of intimai hyperplasia - a review. J Vasc Surg 1991; 13: 85-898.
21. Herrman J.-P. R., Hermans W. R. M., Vos J., Serruys P. W. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? Drugs 1993; 46: 18-52.
22. Weissberg L., Grainger D. J., Shanahan C. M., Metcalfe J. C. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc Res 1993; 27: 1191-1198.
23. Jackson C. L. Animal models of restenosis. TCM 1994; 4: 122-130.
24. Dobrin P. B., Gray J. L., Schwarcz T. H. In vivo models used to study intimai hyperplasia. In: Dobrin P. B. (ed) Intimal Hyperplasia. RG Landes Co., Austin 1994; 75-83.
25. O'Brien E. R. M., de Blois D., Schwarcz S. M. A critical examination of animal models of restenosis following angioplasty. In: Dobrin P. B. (ed) Intimal Hyperplasia. RG Landes Co, Austin. 1994; 229-256.
26. Campbell G. R., Campbell J. Phenotypic modulation of smooth muscle cells in primary culture. In: Campbell G. R., Campbell J. H. (eds) Vascular smooth muscle in culture. 1st ed Boca Raton, Florida, CRC Press 1987; 39-55.
27. Block P. C., Baughman K. L, Pasternak R. C. et al. Transluminal angioplasty: correlation of morphological and angiographic findings in an experimental model. Circulation 1980; 61: 778-785.
28. Castaneda-Zuniga W. R., Formanek A., Tadavarthy M. et al. The mechanism of balloon angioplasty. Radiol 1980; 135: 565-571.
29. Kohchi K., Takebayashi S., Block P. C. et al. Arterial changes after percutaneous transluminal coronary angioplasty: results at autopsy. J Am Coll Cardiol 1987; 10: 592-599.
30. Lyon R. T., Zarins C. K., Lu C.-T. et al. Vessel plaque and lumen morphology after transluminal balloon angioplasty; quantitative study in distended arteries. Arteriosclerosis 1987; 7: 306-314.
31. Zarins C. K., Lu C. T., Gewertz B. L. et al. Arterial disruption and remodelling following balloon dilatation. Surgery 1982; 92: 1086-1095.
32. Holmes D. R. Jr, Vliestra R. E., Mock M. B. et al. Angiographic changes produced by percutaneous transluminal angioplasty. Am J Cardiol 1983; 51: 676-683.
33. Angelini G. D., Breckenridge I. M., Psaila J. V. et al. Preparation of human saphenous vein for coronary artery bypass grafting impairs its capacity to produce prostacyclin. Cardiovasc Res 1987; 21: 28-33.
34. Angelini G. D., Bryan A. J., Williams H. M. et al. Distension promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg 1990; 99: 433-439.
35. Angelini G. D., Breckenridge I. M., Williams H. M., Newby A. C. A surgical preparative technique for human saphenous vein coronary bypass grafts which preserves medial and endothelial functional integrity. J Thorac Cardiovasc Surg 1987; 94: 393-398.
36. Angelini G. D., Bryan A. J., Hunter S., Newby A. C. A simple preparative technique which preserves human saphenous vein functional integrity during coronary artery bypass grafting. Ann Thorac Surg 1992; 53: 871-874.
37. Shwarcz T. H., Dobrin P. B. Role of platelets in the formation of intimai hyperplasia. In: Dobrin PB (ed) Intimal Hyperplasia. RG Landes Co (pub). Austin. 1994; 177-191
38. Wilentz J. R., Sanborn T. A., Haudenschild C. C. et al. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987; 75: 636-642.
39. Tanaka H., Shukova G. K., Swanson S. J. et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-1803.
40. Griesler H. P. The role of monocytes/macrophages in the formation of intimai hyperplasia. In: Dobrin P. B. (ed) Intimal Hyperplasia. RG Landes Co (pub). Austin. 1994; 193-209.
41. Groves H. M., Kinlough-Rathbone R. L, Mustard J. F. Development of non-thrombogenicity of injured rabbit artery despite inhibition of platelet adherence. Arteriosclerosis 1986; 6: 189-196.
42. Allen B. T., Sicard G. A., Welch M. J. et al. Platelet deposition on vascular grafts. The accuracy of in vivo quantification and the significance of in vivo platelet reactivity. Ann Surg 1986; 203:318-325.
43. Yukizane T., Okadome K., Eguchi H. et al. Isotopic study of the effect of platelets on development of intimai thickening in autologous vein grafts in dogs. Br J Surg 1991; 78: 297-302.
44. Dobrin P. B., Littoy F. N., Endean E. D. Mechanical factors predisposing to intimai hyperplasia and medial thickening in autogenous vein grafts. Surgery 1989; 105: 393-400
45. Dobrin P. B. Mechanical factors associated with development of intimai hyperplasia with respect to vascular grafts. In: Dobrin P. B. (ed) Intimal Hyperplasia. RG Landes Co, Austin. 1994; 85-109.
46. Evans L. V., Sumpio B. E. The role of mechanical forces in vitro in the development of intimai hyperplasia. In: Dobrin P. B. (ed) Intimal Hyperplasia. RG Landes Co., Austin. 1994; 111-138.
47. Thompson M. M., Budd J. S., Eady S. L., James R. F. L., Bell P. R. F. Effect of pulsatile stress on endothelial attachment to native vascular surfaces. Br J Surg 1994; 81: 1121-1127.
48. Levine S., Ewels C. J., Rosing D. R. et al. Coronary angioplasty: clinical and angiographic follow-up. Am J Cardiol 1985; 55: 673-676.
49. Ernst S. M. P. G., van der Feltz T. A., Bal E. T. et al. Long term angiographic follow up, cardiac events and survival in patients undergoing percutaneous transluminal coronary angioplasty. Br Heart J 1987; 57: 220-225.
50. Grondin C. M., Thornton J. C. The natural history of vein grafts. In: Coronary artery graft disease. Luscher T. F., Turina M., Braunwald E. (eds) Springer-Verlag, Berlin. 1994; 3-15.
51. FitzGibbon G. M., Leach A. J., Keon W. J. et al. Coronary bypass graft fate: angiographic study of 1179 vein grafts, one year and five years after operation. J Thorac Cardiovasc Surg 1986; 91:773-778.
52. Walts A. E., Fishbein M. C., Matloff J. M. Thrombosed, ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: ten years experience. Am J Heart J 1987; 114: 718-723
53. Hannan E. L., Kilburn H., Racz M. et al. Improving the outcomes of coronary artery bypass surgery in New York State. JAMA 1994; 271: 761-766.
54. Yusuf S., Zucker D., Peduzzi P. et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass surgery trialists collaboration. The Lancet 1994; 344: 563-570.
55. Bourassa M. G., Campeau L., Lesperance J. Changes in grafts and in coronary arteries after coronary bypass surgery. In: Waters D. D., Bourassa M. G. (eds) Care of patients with previous coronary bypass surgery. Cardiovascular Clinics 21/2. Davis (pub) Philadelphia 83-100.
56. Salomon R. N., Hughes C. C. W., Schoen F. J. et al. Human coronary transplantation-associated arteriosclerosis: evidence for a chronis immune reaction to activated graft endothelial cells. Am J Pathol 1991; 138: 791-798.
57. Angelini G., Brayan A. J., Williams H. M. J. et al. Time course of medial and intimai thickening in pig arteriovenous bypass grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg 1992; 103: 1093-1103.
58. Campeau L., Enjalbert M., Lesperance J. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329-1332.
59. Boerboom L. E., Bonchek L. L., Kissebah A. H. et al. Effect of surgical trauma on tissue lipids in primate vein grafts: realtion to plasma lipids. Circulation 1980; 62: 1142-1147.
60. Boncheck L. E., Olinger G. N., Bonchek L. I. et al. The relative influence of arterial pressure versus intraoperative distension on lipid accumulation in primate vein bypass grafts. J Thorac Cardiovasc Surg 1985; 90: 756-764.
61. Drexel H., Amann F. W. Lipids and lipid-lowering drugs and graft function; In: Coronary artery graft disease. Luscher T. F., Turina M., Braunwald E. (eds). Springer-Verlag, Berin. 1994; 3-15.
62. Inagami T., Naruse M., Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 11995; 57: 171-189.
63. Liu M. W., Berk B. C. Restenosis following coronary balloon angioplasty: role of smooth muscle cell proliferation. Trends Cardiovasc Med 1991; 1: 107-111.
64. Dilley R. J., McGeachie J. K., Prendergast F. J. A review of the histological changes in vein to artery grafts with particular reference to intimai hyperplasia. Arch Surg 1988; 123:691-696.
65. Fingerle J., Johnson R., Clowes A. W., Majesky M. W., Reidy M. A. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989; 86: 8412-8416.
66. De Clerck F., Van Gorp L., Beetens J. et al. Arachidonic acid metabolites ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat. Blood Coag Fibrinol 1990; 1: 247-258.
67. Jeremy J. Y., Nystrom M., Barradas M. A., Mikhailidis D. P. Eicosanoids an septicaemia. Prostagl Leukotr Essential Fatty Acids 1994; 50: 287-297.
68. Newby A. C., George S. J. Proposed roles for growth factors in mediating smooth muscle cell proliferation in vascular pathologies. Cardiovasc Res 1992; 27: 1173-1183.
69. Casscells W. Smooth muscle cell growth factors. Prog Growth Factor Res 1991; 3: 177-206.
70. Majesky M. W., Reidy M. A., Bowen-Pope D. F. et al. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990; 111: 2149-2158.
71. Jackson C. L., Raines E. W., Ross R., Reidy M. A. Role of endogenous plateletderived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thrombos 1993; 13: 1218-1226
72. Jackson C. L Pharmacology of smooth muscle cell replication. In: Dobrin P. B. (ed) Intimal Hyperplasia. RG Landes Co., Austin 1994; 259-303.
73. Berk B. C., Alexander R. W. Vasoactive effects of growth factors. Biochem Pharmacol 1989; 38: 219-225
74. Candipan R. C., Hsiun P. T. C., Pratt R., Cooke J. P. Vascular injury augments adrenergic neurotransmission. Circulation 1994; 89: 777-784.
75. Kariya K.-I., Fukumoto Y., Tsuda T. et al. Antiproliferative action of protein kinase C in cultured rabbit aortic smooth muscle cells. Exp Cell Res 1987; 173: 504-514.
76. Nishizuka Y. The molecular heterogeneity of protein kinase and its implications for cellular regulation. Nature 1988; 334: 661-665.
77. Pazin M. J., Williams L. T. Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem Sci 1992; 17: 374-378.
78. Fantl W. J., Johnson D. E., Williams L. T. Signaling by receptor tyrosine kinases. Annu Rev Biochem 1993; 62: 453-481.
79. Rozengurt E. Early signals in the mitogenic response. Science 1986; 234: 161-166.
80. Simons M., Roenberg R. D. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation, in vitro. Circ Res 1992; 70: 835-843
81. Hutchinson H. G., Shi Y., Sigman S. et al. Inhibition of human vascular smooth muscle cell proliferation using c-myc antisense oligonucleotides. Circulation 1992; 86: (suppl 1): 1226 (abstr)
82. Simons M., Edelman E. R., De Keyser J. L. et al. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
83. Miano J. M., Tota R. R., Vlasic N. et al. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol 1990; 137: 1939-1945
84. Foegh M. L., Virmanoi R. Molecular Biology of Intimal Proliferation. In: Yacoub M., Pepper J. (eds) Annual of Cardiac Surgery. Current Science Ltd, London 1994; 63-65.
85. Clowes A. W., Schwartz S. M. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985; 56: 139-146.
86. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992; 86: 723-729.
87. Nikkari S. T., Jarvelainen H. T., Wight T. N. et al. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol 1994; 144: 1348-1356.
88. Wight T. N. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-20.
89. Ang A. H., Tachas G., Campbell J. H. et al. Collagen synthesis by cultured rabbit aortic smooth muscle cells. Alterations with phenotype. Biochem J 1990; 265: 461-469.
90. Majors A. K., Eckhart L. A. Cell density and proliferation modulate collagen synthesis and pro-collagen mRNA levels in arterial smooth muscle cells. Exp Cell Rest 1992; 200: 168-174.
91. Galis Z. S., Sukhova G. K., Lark M. W. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
92. Thie M., Harrach B., Schonherr E. et al. Responsiveness of aortic smooth muscle cells to soluble growth mediators is influenced by cell-matrix contact. Arterioscler Thromb 1993; 13: 994-1003.
93. Southgate K. M., Izzat M. B., Knight D., Angelini G. D. Up regulation of matrix degrading gelatinases in pig saphenous vein grafts. (abstr) Br Heart J 1995; in press.
94. Southgate K. M., Izzat M. B., Davies A. H. et al. Up regulation of metalloproteinases in an organ culture of saphenous vein. J Mol Cell Cardiol 1994; 26: CCLI
95. Zempo N., Kenagy R. D., Au Y. P. T. et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994; 20: 209-217.
96. Southgate K. M., Davies M., Booth R. F. G., Newby A. C. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J 1992; 288: 93-99
97. Alvani M., Moore S. Glycosaminoglycan composition and biosynthesis in the endothelium-covered neointima and deendothelialized rabbit aorta. Exp Mol Pathol 1985; 42: 389-400.
98. Clowes A. W. Regulation of smooth muscle cell function by heparin. J Vasc Surg 1992; 15: 911-913.
99. Murphy G., Atkinson S., Ward R. et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1-12.
100. Clowes A. W., Clowes M. M., Au Y. P. T. et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
101. Jackson C. L., Reidy M. A. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 1992; 667: 141-150.
102. Jackson C. L., Raines E. W., Ross R., Reidy M. A. Role of endogenous platelet derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thrombos 1993; 13: 1218-1226.
103. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-808.
104. 2: its generation and role in platelet activation. Prog Lipid Res 1989; 28: 273-301.
105. Deby C. Metabolism of polyunsaturated fatty acids, precursors of eicosanoids. In : Curtis-Prior (ed) Prostaglandins. Biology and Chemistry of Prostaglandins and Related Eicosanoids. Churchill Livingstone, Edinburgh 1988; 11-36.
106. Eldor E., Falcone D. J., Hajjar D. P. et al. Recovery of prostacyclin production by de-endothelialized rabbit aorta: critical role of neointimal smooth muscle. J Clin Invest 1981; 67: 735-741.
107. 2 in spontaneously hypertensive rats and its role in the rapid proliferation of vascular smooth muscle cells. Hypertension 1988; 12: 46-51.
108. Ishimitsu T., Uehara Y., Ishii M. et al. Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats. Hypertension 1988; 1: 46-51.
109. 2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. Atherosclerosis 1988; 72: 245-248.
110. 2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase. J Biol Chem 1994; 269: 5693-5698.
111. Crowley S. T., Dempsey E. C., Horwitz K. B., Horwitz L. D. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-1918.
112. Palmberg L. H.-E., Claesson H.-E., Thyberg J. Leukotrienes stimulate initiation of DNA synthesis in cultured arterial smooth muscle cells in primary culture. J Cell Sci 1987; 88: 151-159.
113. Palmberg L. H.-E., Claesson H-E., Thyberg J. Effects of leukotrienes on phenotypic properties and growth of arterial smooth muscle cells in primary culture. J Cell Sci 1989; 93: 403-408.
114. 4: a role for mediation of interleukin 1. Atherosclerosis 1995; 113: 11-18.
115. Nakao J., Ito H., Chang W. et al. Aortic smooth muscle cell migration caused by platelet derived growth factor is mediated by lipoxygenase products of arachidonic acid. Biochem Biophys Res Commun 1983; 112: 866-871.
116. Rao G. N., Lassegue B., Griendling K. K., Alexander R. W. Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: role of arachidonic acid. Oncogene 1993; 8: 2759-2765.
117. Serhan C. N. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim et Biophvsica Acta 1994; 1212: 1-25.
118. Hadhazy P., Malomvolgyi B., Magyar K. Endogenous prostanoids and arterial contractility. Prostagl Leukotr Essential Fatty Acids Revs 1988; 32: 175-200.
119. Tsang V., Jeremy J. Y., Mikhailidis D. P. et al. The release of prostacyclin by the human aorta. Cardiovasc Rest 1988; 22:489-493.
120. 2 production by endothelial cells smooth muscle cells and fibroblasts cultured from piglet aorta. Biochim Biophys Acta 1982; 712: 103-110.
121. Piomelli D., Feinmark S. J, Canon P. J. Leukotriene biosynthesis by canine and human coronary arteries. J Pharmacol Exp Ther 1987; 241: 763-770.
122. 2 and prostacyclin. Pharmacol Revs 1979; 30: 293-331.
123. Ham E. A., Soderman D. D., Zanetti et al. Inhibition by prostaglandins of leukotriene release from activated neutrophils. Proc Natl Acad Sci 1983; 80: 4349-4353
124. Jones G., Hurley J. V. The effect of prostacyclin on the adhesion of leucocytes to injured vascular endothelium. J Pathol 1984; 142: 51-60.
125. Weksler B. B., Goldstein I. M. Prostaglandins: interactions with patelets and polymorphonuclear cells in haemostasis and inflammation. Am J Med 1980; 68: 419-428.
126. Belch J. J. F., Saniabadi A., Forbes C. D. The effect of iloprost on white cell bahaviour. In: Schror K., Gryglewski R. J. (eds) Prostacyclin and its Stable Analogue Iloprost. Springer Verlag, Berlin 1986; 97-102.
127. Huttner J. J., Gwebu E. T., Panganamala R. V. Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells. Science 1977; 197: 289-291.
128. Libby P., Warner S.J. C., Friedman G. B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth inibitory prostaglandins. J Clin Invest 1988; 81: 487-493.
129. Pomerantz K. B., Hajjar D. P. Eicosanoids in the regulation of arterial smooth muscle cell phenotype, proliferative capacity and cholesterol metabolism. Arteriosclerosis 1989; 9: 413-429.
130. 1 inhibits DNA synthesis in arterial smooth muscle cell stimulated with platelet derived growth factor. Atherosclerosis 1984; 53: 77-84
131. Owen N. Prostacyclin can inhibit DNA synthesis in vascular smooth muscle cells. In: Prostaglandins leukotrienes and lipoxins. Biochemistry, mechanisms of action and clinical applications. Plenum Press, New York: 1985; 193-205.
132. Wickremasinghe R. G. The role of prostaglandins in the regulation of cell proliferation. Prostagl Leuk Essential Fatly Acids 1988; 31: 171-180.
133. Jackson C. L., Schwartz S. M. Pharmacology of smooth muscle cell replication. Hypertension 1992; 20: 713-736.
134. 2 analogues on cAMP levels in cultured endothelial cells derived from bovine arteries. Naunyn Schmiedeberg's Arch Pharmacol 1980; 311: 67-70.
135. Di Marzo V. Archidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostagl Leukotr Essential Fatty Acids 1995; In press.
136. 2 and phospholipase C metabolites. Life Sci 1991; 49: 247-260.
137. 2 analogues on cAMP levels in cultured endothelial cells derived from bovine arteries. Naunyn Schmiedebergs Arch Pharmacol 1980; 311: 67-70.
138. Stout R. Cyclic AMP: a potent inhibitor of DNA synthesis in cultured arterial endothelial and smooth muscle cells. Diabetologia 1982; 22: 51-55.
139. Khoo J., Mahoney E., Steinberg D. Neutral cholesterol esterase activity and its enhancement of cAMP-dependent protein kinase. J Biol Chem 1981; 256: 12659-12661
140. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem J 1992; 288: 527-532
141. Kempski O., Wroblewska B., Spatz M. Effects of forskolin on growth and morphology of cultured glial and cerebrovascular endothelial and smooth muscle cells. Int J Dev Neurosci 1987; 5: 435-445.
142. Yu S.-M., Cheng Z.-J., Kuom S.-C. Antiproliferative effects of A02011-1 an adenyl cyclase activator in cultured vascular smooth mucle cells of rat. Br J Pharmocol 1995; 114: 1227-1235
143. Bennett M. R., Evan G. L., Newby A. C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction interferon-t, heparin and cyclic nucleotide analogues and induces apoptosis. Circ Res 1994; 74: 525-536.
144. Virdee K., Brown B. L., Dobson P. R. M. Stimulation of archidonic acid release from Swiss 3T3 cells by recombinant basic fibroblast growth factor. Biochim Biophys Acta 1994; 12220: 171-180.
145. Daniel T. O., Gibbs V. C., Milfay D. F., Williams L. T. Agents that increase cAMP accumulation block endothelial c-sis induction by thrombin and tranforming growth factor-beta. J Biol Chem 1987; 262: 11893-11899.
146. 2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res 1992; 71: 1305-1313.
147. Powell J. T., Higman D. J. Smoking, nitric oxide and the endothelium. Br J Surg 1994; 81: 785-787.
148. Komori K., Okadome K., Sugimachi K. Endothelium derived relaxing factor and vein grafts. Br J Surg 1991; 78: 1027-1030.
149. Garg L. C., Hassid S. Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 893: 1774-1777.
150. Vane J. R., Anggard E. E., Botting R. M. Regulatory functions of the vascular endothelium. New Engl J Med 1990; 323: 27-37
151. Bredt D. S., Snyder S. H. Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem 1994; 63: 175-195.
152. Salvemini D., Misko T. P., Seibert K. et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-7244.
153. Salvemini D., Settle S. L., Masferrer J. L. et al. Regulation of prostaglandin production by nitric oxide: an in vivo analysis. Br J Pharmacol 1995; 114: 1171-1178
154. Woessner J. F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J 1991; 5: 214-154.
155. 2: selective enhancement of collagenase gene expression in human dermal fibroblasts. J Cell Biochem 1994; 54: 465-472.
156. Iacoviello L., De Gurtis A., D'Adamo C. et al. Prostacyclin is required for t-PA release after venous occlusion. Am J Physiol 1994; 266: H429-H434.
157. Hennig B., Lipkje D. W., Boissonneault G. A., Ramasamy S. Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Prostagl Leukotr Essential Fatty Acids 1995; In press.
158. Pietila K., Moilanen T., Nikkari T. Prostaglandins enhance the synthesis of glycosaminoglycans and inhibit the growth of rabbit arterial smooth muscle cells in culture. Artery 1980; 7: 509-518.
159. Hajjar D. P., Pomerantz K. B. Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. FASEB J 1992; 6: 2933-2941.
160. Hajjar D. P., Weksler B. B., Falcone D. J. et al. Prostacyclin modulates cholestoryl ester hydrolytic activity by its effect on cAMP in rabbit aortic smooth muscle. J Clin Invest 1982; 70: 479-488.
161. Sinzinger H., Rogatti W. Prostaglandins and arterial wall lipid metabolism. J Physiol Pharmacol 1994; 45: 27-40.
162. Kuriyama H., Makita Y. Modulation of neuromuscular transmission by endogenous prostaglandins in guinea pig mesenteric artery. J Physiol (London) 1982; 327: 431-448.
163. Cooke J. P., Dasari P., Krieger J. E. et al. Persistent endothelial and adrenergic dysfunction after angioplasty. J Am Coll Cardiol 1991; 17: 59A (abstr)
164. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 11938-11944.
165. Bergstrom S., Carlson L. A., Weeks J. R. The prostaglandins: a family of biologically active lipids. Pharmacol Revs 1968; 20: 1-48.
166. Horrobin D. F. Interactions between n-3 and n-6 essential fatty acids in the regulation of cardiovascular disorders and inflammation. Prostagl Leukotr Essential Fatty Acids 1991; 44: 127-131.
167. Horrobin D. F. Omega-6 and omega-3 essential fatty acids in atherosclerosis. Seminars Thrombosis Hemostas 1993; 19: 129-137.
168. Kinsella J. E., Lokesh B., Stone R. A. Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. Am J Clin Nutr 1990; 52: 1-28.
169. Malle E., Kostner G. M. Effects of fish oils on lipid variables and platelet function indices. Prostagl Leukotr Essential Fatty Acids 1993; 49: 645-663.
170. Jeremy J. Y. Long chain fatty acids in obstetrics gynecology and fertility: a focus on non-eicosanoid mediated mechanisms. In: Bracco U., Deckelbaum R. J. (eds) Polyunsaturated fatty acids in human nutrition. Nestle Nutrition Workshop Series 1992; 28; 179-194.
171. Horrobin D. F. Hypothesis: Abnormal membrane concentrations of 20 and 22 carbon essential fatty acids as the fundamental lesion producing coronary and peripheral vascular disease. Prostagl Leukotr Essential Fatty Acids 1995; In press.
172. Shiina T., Terano T., Saito J. et al. Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells. Atherosclerosis 1993; 104: 95-103.
173. Tomasaka L, Resnick R. J. Suppression of platelet-derived growth factor receptor tyrosine kinase activity by unsaturated fatty acids. J Biol Chem 1993; 268: 5317-5322.
174. Fox P. L., Di Corleto P. E. Fish oils inhibit endothelial cell production of platelet derived growth factor-like protein. Science 1988; 241: 453-457
175. Fox P. L., Salvatore M. F. Serum factor that blocks the action of fish oils on endothelial cell production of platelet derived growth factor is ceruloplasmin. Lab Invest 1992; 66: 467-477.
176. McPhail L. C., Clayton C. C., Snyderman R. A protein second messenger role for unsaturated fatty acid activation of calcium dependent protein kinase C. Science 1984; 224: 622-625.
177. Murukami K., Routtenberg A. Direct activation of purified protein kinase C by unsaturated fatty acids (oleic and arachidonic acid) in the absence of phospholipids and calcium. FEES Lett 1985; 192: 189-193.
178. Seifert R., Schachtele C., Schultz G. Activation of protein kinase C by cis-and trans-octadecanoic acid in intact human platelets and its potentiation by diacylglycerol. Biochim Biophys Res Commun 1988; 149: 762-768.
179. 2+ dependent K+ channel activity in smooth muscle cells. Proc Roy Soc Lond (Biol) 1989; 237: 259-266.
180. Boltina V., Omelyanenko V., Heyes B. et al. Variations of membrane cholesterol alter kinetics of calcium-dependent K+ channels and membrane fluidity in vascular smooth muscle cells. Pflugers Arch 1989; 415: 262-268
181. Bregetowski P. D., Priseva O. Yu, Serbryakov V. et al. Comparison of Ca2+ dependent K+ channels in the membrane of smooth muscle cells, isolated from adult and fetal human aorta. Pfluger's Arch 1988; 413: 8-13.
182. Karnovsky M. J., Kleinfeld A. M., Hoover R. L. et al. The concept of lipid domains in membranes. J Cell Biol 1982; 94: 1-6.
183. Glass D. B., Frey W., Carr D. W., Goldberg N. D. Stimulation of human platelet guanylate cyclase by fatty acids. J Biol Chem 1977; 252: 1279-1285.
184. Froud R. J., East J. M., Jones O. T., Lee A. G. Effects of lipids and long chain alkyl derivatives on the activity of (Ca2H-Mg2+)-ATPase. Biochem 1986; 25: 7544-7552.
185. Bevilacqua M., Pober J., Mendrick D. et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238-9242.
186. Springer T. Adhesion receptors of the immune system. Nature 1990; 346: 425-434.
187. Cybulsky M., Gimbron M. J. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-791.
188. De Caterina R., Cybulsky M. I., Clinton S. K. et al. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and pro-inflammatory proteins in human endothelial cells. Arterioscler Thrombos 1994; 14: 1829-1836.
189. 4 receptor. Prostagl Leukotr Essential Fatty Acids 1995; 52: 293-298.
190. Coughlin S. R., Moskowitz M. A., Zetter B. A. et al. Platelet dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature 1980; 288: 600-608.
191. Ristimaki A., Viinikka L. Modulation of prostacyclin production by cytokines in vascular endothelial cells. Prostagl Leukotr Essential Fatty Acids 1992; 47: 93-99.
192. Rossi V., Brevario F., Ghezzi P. et al. Prostacyclin synthesis induced in vascular cells by interleukin 1. Science 1985; 229: 174-176.
193. Test S. T., Bang N. U. Platelet activating factor stimulates prostacyclin synthesis by cultured endothelial cells. Thrombos Haemostas 1981; 46: 269-279.
194. Hallam T. J., Pearson J. D., Needham L. A. Thrombin-stimulated elevation of human endothelial cell cytoplasmic free calcium concentrations causes prostacyclin production. Biochem J 1988; 251: 243-249.
195. Carter T. D., Eisert W. G., Muller T. H. Thrombin stimulates inositol phosphate accumulation and prostacyclin synthesis in human endothelial cells from umbilical vein but not omentum. Thrombos Haemostas 1989; 61: 122-126.
196. Sinzinger H., Zidek T., Kaliman J. Stimulation of prostacyclin formation by platelet derived growth factor: an important pathomechanism for atherogenesis. Exp Pathol 1988; 34: 881-886.
197. Blay J., Hollenberg M. Epidermal growth factor stimulation of prostacyclin by cultured aortic smooth muscle cells: requirements for increased cellular calcium levels. J Cell Physiol 1989; 139: 524-530.
198. Jeremy J. Y., Mikhailidis D. P., Dandona P. Excitatory receptor-linked prostanoid synthesis in mammalian smooth muscle: the role of calcium, protein kinase C and G proteins. Prostagl Leuk Essential Fatty Acids Revs 1988; 34: 215-228.
199. 2+ concentrations beneath the plasma membrane and the activation of protein kinase C. Biochim Biophys Acta 1993; 1179: 81-88.
200. Habenicht A. J. R., Goerig M., Grulich J. et al. Human platelet growth factor stimulates rapid prostaglandin synthesis by activation and by rapid de novo biosynthesis of cyclooxygenase. J Clin Invest 1985; 75: 1381-1387.
201. Lin A. H., Bienowski M. J., Gorman R. R. Regulation of prostaglandin H. synthase mRNA levels and prostaglandin biosynthesis by platelet derived growth factor. J Biol Chem 1989; 264: 17378-17283.
202. Richmarchin J. A., Jacobson J. A., Szabo P. et al. Regulation of cyclooxygenase - 2 expression in aortic smooth muscle cells. Arterioscler Thromb 1994; 14: 1021-1031.
203. Goppelt-Struebe M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostagl Leukotr Essential Fatty Acids 1995; 52: 213-222.
204. 2 isomerase in NIH3T3 and pEj transformed fibroblasts. Biochem Biophys Res Commun 1994; 198: 298-303.
205. Jeremy J. Y., Mikhailidis D. P., Dandona P. The thromboxane A2 analogue U46619 stimulates vascular prostacyclin synthesis. Eur J Pharmacol 1985; 51: 837-842.
206. Coughlin S. R., Moskowitz M. A., Antoniades H. N., Levine L. Serotonin receptor-mediated stimulation of bovine smooth muscle cell prostacyclin synthesis and its modulation by platelet-derived growth factor. Proc Natl Acad Sci USA 1981; 78: 7134-7138.
207. Jeremy J. Y., Dandona P. The role of the diacyl glycerol-protein kinase C system in mediating adrenoceptor-prostacyclin synthesis coupling in the rat aorta. Eur J Pharmacol 1987; 211: 73-77.
208. Jeremy J. Y., Mikhailidis D. P., Dandona P. Adrenergic modulation of vascular prostacyclin synthesis. Eur J Pharmacol 1985; 114: 33-40.
209. Blumberg A. L., Denny S. E., Marshall G. R., Needleman P. Blood vesselhormone interactions: angiotensin, bradykinin and prostaglandins. Am J Physiol 232; H305-H310.
210. Satoh H., Suzuki J., Satoh S. Effects of calcium antagonists and calmodulin inhibitors on angiotensin II - induced prostaglandin production in the isolated dog renal arteries. Biochem Biophys Res Commun 1985; 126: 464-470.
211. Hassid A., Williams C. Vasoconstrictor evoked prostaglandin synthesis in cultured vascular smooth muscle. Am J Physiol 1982; 245: C278-C284.
212. Baezinger N. L., Fogerty F. J., Mertz L. F., Chernuta L. F. Regulation of histamine-mediated prostacyclin synthesis in cultured human vascular endothelial cells. Cell 1981; 24: 915-923.
213. Boeynaems J. M., Galand N. Cholinergic stimulation of vascular prostacyclin synthesis. Prostaglandins 1983; 26: 531-561.
214. Boeynaems V. M., Galand N. Stimulation of prostacyclin synthesis by extracellular ADP and ATP. Biochem Biophys Res Commun 1983; 112: 291-300.
215. 1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet derived growth factor. Atherosclerosis 1984; 53: 77-84.
216. Geisterfer A. T., Peach M. J., Owens G. K. I. Angiotensin II induces hypertrophy, not hyperplasia of cultured rat aortic smooth muscle cells. Circ Res 1988; 62: 749-756.
217. Prescott M. G., Webb R. L., Reidy M. A. Angiotensin converting enzyme inhibitor versus angiotensin II receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathl 1991; 139: 1291-1296.
218. Daemen M. J., Lombardi D. M., Bosman F. T., Schwartz S. M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-456.
219. Bailey W. L., LaFleur D. W., Forrester J. S., Fagin J. A., Sharifi B. G. Stimulation of rat vascular smooth muscle cell glycosaminoglycan production by angiotensin II. Atherosclerosis 1994; 111: 55-64
220. Huckle W. R., Prokop C. A., Dy R. C., Herman B., Earp S. Angiotensin II stimulates protein tyrosine phosphorylation in a calcium dependent manner. Mol Cell Biol 1990; 10: 6299-6308.
221. Griedling K. K., Rittenhouse S. E., Brock T. A. et al. Sustained diacylglycerol formation from inositol phospholipids in angiotensin-II stimulated vascular smooth muscle cells. J Biol Chem 1986; 261: 5901-5909.
222. Taubman M. B., Berk B. C., Izumo S. et al. Angiotensin II induces c-fos mRNA in aortic smooth muscle cells. Role of calcium mobilization and protein kinase C activation. J Biol Chem 1989; 264: 526-532.
223. Naftilan A. J., Gilliand G. K., Eldridge C. S., Kraft A. S. Induction of the protooncogene c-jun by angiotensin II. Mol Cell Biol 1990; 19: 5536.
224. Sharifi B. G., LaFleur D. W., Pirola C. J., Forrester J. S., Fagin J. A. Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem 1992; 267: 23910.
225. Satoh T., Sugama K., Matsuo A. et al. Histamine as an activator of cell growth and extracellular matrix reconstruction for human vascular smooth muscle cells. Atherosclerosis 1994; 110:53-61.
226. Bell L., Madri J. A. Effect of platelet factors on migration f cultured bovine aortic endothelial cells. Circ Res 1989; 65: 1057-1065.
227. Hirata Y., Takai Y., Fukuda Y., Marumo F. Endothelin is a potent mitoge for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225-232.
228. Komuro I., Kurihara H., Sugiyama T. et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238: 249-258
229. Blaes N., Boissel J.-P. Growth stimulating effect of catecholamines on rat aortic smooth muscle cells. J Cell Physiol 1983; 116: 167-172.
230. Majesky M. W., Reidy M. A., Benditt E. P., Jachau M. R. Focal smooth muscle cell proliferation in the aortic intima produced by an initiation-promotion sequence Proc Natl Acad Sci USA. 1985; 82: 3450-3454.
231. Majesky M. W., Daemen M. J. A. P., Schwartz S. M. Alpha1 adrenergic stimulation of platelet-derived growth factor A-chain gene expression in rat aorta. J Biol Chem 1990; 265: 108-1088.
232. Sharefkin J. B., Diamond S. L, Eskin S. G. et al. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells. J Vasc Surg 1991; 12: 1-10.
233. Murase T., Kozawa O., Miwa M. et al. Regulation of proliferation by vasopressin in aortic smooth muscle cells: function of protein kinase C. J Hypertens 1992; 10: 1505-1512.
234. Oiso Y., Kotoyori J., Murase T. et al. Effect of pituitary adenylate cyclase activating polypeptide on vasopressin - induced proliferation of aortic smooth muscle cells: comparison with vasoactive intestinal polypeptide. Biochem Cell Biol 1993; 71: 156-164.
235. Nemeck G. M., Coughlin S. R., Handley D. A., Moskowitz M. A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 83: 674-678.
236. Brinkman H.-J. M., van Buul-Wortelboer M. F., van Mourik J. A. Involvement of cyclooxygenase and lipoxygenase-mediated conversion of arachidonic acid in controlling human vascular smooth muscle cell proliferation. Thrombos Haemostas 1990; 63: 291-297.
237. Flower R. J. Lipocortin and the mechanism of action of glucocorticoids. Br J Pharmacol 1988; 94:987-1015.
238. Bailey J. M., Makheja A.N., Pash J., Verma M. Corticosteroids suppress cyclooxygenase messenger RNA levels and prostanoid synthesis in cultured vascular cells. Biochem Biophys Res Commun 1988; 157: 1159-1163.
239. Jeremy J. Y., Dandona P. Inhibition by hydrocortisone of prostacyclin synthesis by rat aorta and its reversal with the antiglucocorticoid RU486. Endocrinol 1986; 119: 666-675.
240. Ito Y., Kozawa O., Tokuda H. et al. Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smoth muscle cells. Atherosclerosis 1994; 110: 69-76
241. Morisaki N., Kanzaki T., Matoyama N. et al. Cell cycle - dependent inhibition of DNA synthesis by prostaglandin 12 in cultured rabbit aortic smooth muscle cells. Atherosclerosis 1988; 71: 165-171.
242. 2 in intimal smooth muscle cells from rabbits. Atherosclerosis 1988; 73: 67-69.
243. Jeremy J. Y., Mikhailidis D. P. NSAID efficacy and side effects: are they wholly prostaglandin mediated? J Drug Develop 1990; 3: 3-4.
244. Jeremy J. Y., Mikhailidis D. P., Dandona P. Differential inhibitory potencies of non-steroidal antinflammatory drugs on smooth muscle prostanoid synthesis. Eur J Pharmaco 1990; 182: 83-89.
245. Gill J., Dandona P., Jeremy J. Y. Indomethacin and ibuprofen inhibit the uptake of [45Ca2+] by human platelets through a thromboxane A2 independent mechanism. Eur J Pharmacol 1990; 187: 135-138.
246. Abramson S. B., Weissman G. The mechanisms of action of non-steroidal antiiinflammatory drugs. Arthrit Rheum 1989; 32:1-9.
247. deMello M. C. F., Bayer B. B., Beaven M. A. Evidence that prostaglandins do not have a role in the cytostatic action of antiinflammatory drugs. Biochem Pharmacol 1980; 29: 311-320.
248. Jeremy J. Y., Mikhailidis D. P. Eicosanoids and drug action. J Drug Develop 1993; 6: 1-3.
249. Jeremy J. Y., Mikhailidis D. P., Dandona P. Angiotensin converting enzyme inhibitors antagonize in vitro adrenoceptor- and muscarine receptor linked prostanoid synthesis: evidence for calcium channel blockade. Agents Action 1988; 24: 381-386.
250. Jererny J. Y., Mikhailidis D. P., Dandona P. The effect of nifedipine, nimodipine and nisoldipine on agonist and trauma stimulated vascular prostacyclin synthesis. Naunyn Schmied Arch Pharmacol 1986; 332: 70-73.
251. Gill J., Jeremy J. Y., Dandona P. Captopril inhibits influx of calcium into human platelets. Eur J Pharmacol 1989; 162: 193-194.
252. Jeremy J. Y., Gill J., Mikhailidis D. P. Effect of milrinone on human platelet cAMP phosphodiesterase, iloprost-stimulated cAMP, thromboxane A2 generation and calcium uptake. Eur J armacol-Molec Pharm 1993; 245: 67-73.
253. Mattson E., Brunkwall J., Fait K., Berqvist D. Vessel repair after balloon angioplasty: morphological appearance and prostacyclin synthesising capacity. Eur J Vasc Surg 1992; 6: 585-592.
254. Cragg A., Einzig S., Castaneda-Zuniga W., Amplatz K. et al. Vessel wall arachidonate metabolism after angioplasty: possible mediators of postangioplasty vasospasm. Am J Cardiol 1983; 51: 1441-1445.
255. Jeremy J. Y., Dandona P. Effect of endothelium removal on stimulatory and inhibitory modulation of rat aortic prostacyclin synthesis. Br J Pharmacol 1989; 96: 243-250.
256. Karatapanis S., Stansby G., Rolles K., McCormick A., Jacobs M., Jeremy J. Y. Effect of liver and kidney preservation solutions on contraction and relaxation and prostacyclin production by the rabbit aorta, in vitro. J Hepatol 1993; 19: 71-78.
257. Jeremy J. Y., Izzat M. B., Knight D., Birkett S., Angelini G. D. Reduced prostacyclin and increased leukotriene B4 synthesis by porcine vein grafts. Ann Thorac Surg 1996; In press.
258. 2 like substance in experimental hypertension. Protagl Med 1979; 3: 251-256.
259. 2, a potent hypotensive substance, by rat aortic rings and homogenates of spontaneously hypertensive rats. Prostaglandins 1978; 15: 1005-1012.
260. Rioux F., Regoli D. In vitro production of prostaglandins by isolated aorta strips of normotensive and hypertensive rats. Canadian J Physiol Pharmacol 1985; 53: 673-677.
261. Prasad A., Logan S., Nerem R., Schwartz C., Sprague E. Flowrelated responses of intracellular inositol phosphate levels in cultured aortic endothelial cells. Circ Res 1993; 72: 827-836.
262. Nollett M., Eskin S., McIntire L. Effect of flow on archidonic acid metabolism in human endothelial cells. Biochim Biophys Acta 1989; 1005: 72-78
263. Jeremy J. Y., Karatapanis G., Mikhailidis D. P., McCormick A. Alterations of receptor-linked prostacyclin synthesis in the heptic portal veinligated rat. J Hepatol 1994; 21: 1017-1022.
264. Hamilton G., Phing R. C. F., Hutton R. A. et al. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982; 2: 236-242.
265. Grabowski E. F., Jaffe E. A., Weksler B. B. Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. J Lab Clin Med 1985; 105: 36
266. Frangos J. A., Eskin S. G., McIntire L V., Ives C. L. Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985; 227: 1477
267. 1 and thromboxane B2 in ex vivo perfused canine veins. J Vase Surg 1988; 7: 99
268. 2 release in ex vivo perfused canine vessels. Effects on pulse rate, pulsatility altered pressure and flow rate. Eur J Vase Surg 1989; 3: 219
269. 2 biosynthesis or capacities of heart arteries and platelets at various stages of experimental atherosclerosis in rabbits. Atherosclerosis 1978; 31: 385-394.
270. Larrue J., Rigaud M., Daret O. et al. Prostacyclin production by cultured smooth muscle cells from atherosclerotic rabbit aorta. Nature 1980; 285: 480-482.
271. Israel D. H., Adams P. C., Stein B. et al. Anti-thrombotic therapy in the coronary vein graft patient. Clin Cardiol 1991; 14: 283-295.
272. Jeremy J. Y., Mikhailidis D. P., Stansby G., Hamilton G. NSAIDs : possible use in the prevention of restenosis. J Drug Development 1994 6: 91-92.
273. Jeremy J. Y., Bryan A. J., Angelini G. D. The pathophysiology and treatment of vein graft failure. J Drug Develop Clinical Practice 1995; In press.
274. Henderson W., Moritz T., Goldman S. et al. The statistical analysis of graft patency data in a clinical trial of anti-platelet agents following coronary artery bypass grafting. Control Clin Trials 1988; 9: 189-205.
275. Antiplatelet Trialists Collaboration. BMJ 1994; 308: 159-167.
276. Goldman S., Copeland J., Moritz T. et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy. Circulation 1988; 77: 1324-1332.
277. Goldman S., Copeland J., Moritz T. et al. Saphenous vein graft patency one year after coronary artery bypass surgery and effect of antiplatelet therapy. Circulation 1989; 80: 1190-1197.
278. Goldman S., Copeland J., Moritz T et al. Internal mammary artery and saphenous vein graft patency: effects of aspirin. Circulation 1990; 82 (suppl IV): IV-237-242.
279. Goldman S., Copeland J., Moritz T. et al. Long term graft patency (3 years) after coronary artery surgery. Effects of aspirin : results of a VA cooperative study. Circulation 1994; 89: 1138-1143.
280. Brady A. J., Warren J. B. Angioplasty and stenosis. Br Med J 1981; 303: 729-730.
281. Hoet B., Falcon C, DeReys S. et al. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 1990; 75: 646-653.
282. 2/ prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 1994; 89: 588-595.
283. Timmermans C., Verhaecke J., Vrolix M. et al. Ridogrel in the setting of percutaneous transluminal coronary angioplasty. Am J Cardiol 1991; 68: 463-466.
284. Schwartz L S., Bourassa M. G., Lesperance J. et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 171-1719.
285. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br Heart J1994; 71: 7-15.
286. 1 in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application. Thromb Res 1988; 50: 749-755.
287. 1 analog misoprostol. J Rheumatol 1991; 18: 1461-1465.
288. Simpson P. J., Mickelson J., Fantone J. C. et al. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. J Rheumatol 1991; 18: 1461-1465.
289. Demke D. M., for the Ciprostene Study Group. Double blind, placebo controlled efficacy study of ciprostene (U-61,431F) in percutaneously transluminal coronary angioplasty (PTCA). Br J Haematol 1990; 76: 20
290. 1 and isosorbate dinitrate in peripheral vascular disease. Lancet 1990; 335: 627-628.
291. 1 often prevents cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation 1994; 89: 1786-1791.
292. Folts J. D., Crowell E. B., Rowe G. G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370.
293. Golino P., Buja L. M., Ashton J. H. et al. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1988; 78: 701-711.
294. 2 receptor antagonists. Circ Res 1986; 59: 568-578.
295. 2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine induced canine coronary cyclic flow variations. J Am Coll Cardiol 1990; 16: 705-713.
296. Eichorn E. J., Grayburn P. A., Willard J. E. et al. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J. Am Coll Cardiol 1991; 17: 43-52.
297. Leaf A., Jorgensen M. B., Jacobs A. K. et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994; 90: 2248-2257
298. Lau C. S., Belch J. J. E, Mackay I. R., Shaw J. W. Restensosis following transcutaneous balloon angioplasty for peripheral arterial disease: a double blind, placebo controlled trial of omega-6 fatty acid. 9th International Congress on Protaglandins. Florence 4-9 June, 1994, Abstract book.